Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 30:14:565.
doi: 10.1186/s12879-014-0565-5.

Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study

Naho Tsuchiya  1   2 , Panita Pathipvanich  3 , Nuanjun Wichukchinda  4 , Archawin Rojanawiwat  5 , Wattana Auwanit  6 , Koya Ariyoshi  7   8 , Pathom Sawanpanyalert  9
Affiliations

Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study

Naho Tsuchiya et al. BMC Infect Dis. .

Abstract

Background: Antiretroviral therapy markedly reduced mortality in HIV-infected individuals. However, in the previous studies, up to 50% of patients are compelled to modify their regimen in middle and low-income countries where salvage drug is still limited. This cohort study aimed to investigate the incidence and predictors of regimen modification from the first-line antiretroviral regimen in northern Thailand.

Methods: All HIV-infected patients starting antiretroviral therapy (ART) with generic drug (GPOvir®; stavudine, lamivudine and nevirapine) at a governmental hospital in northern Thailand from 2002 to 2007 were recruited. Baseline characteristics and detailed information of regimen modification until the end of 2010 were ascertained from cohort database and medical charts. As a potential genetic predictor of regimen modification, HLA B allele was determined by bead-based array hybridization (WAKFlow® HLA typing kit). We investigated predictors of the regimen modification using Cox's proportional hazard models.

Results: Of 979 patients, 914 were eligible for the analysis. The observed events of regimen modification was 377, corresponding to an incidence 13.8/100 person-year-observation (95% CI:12.5-15.3) over 2,728 person years (PY) follow up. The main reasons for regimen modification were adverse effects (73.5%), especially lipodystrophy (63.2%) followed by rash (17.7%). Sixty three patients (17.1%) changed the regimen due to treatment failure. 2% and 19% of patients had HLA-B*35:05 and B*4001, respectively. HLA-B*35:05 was independently associated with rash-related regimen modification (aHR 7.73, 95% CI:3.16-18.9) while female gender was associated with lipodystrophy (aHR 2.11, 95% CI:1.51-2.95). Female gender (aHR 0.54, 95% CI: 0.30-0.96), elder age (aHR 0.56, 95% CI: 0.32-0.99) and having HLA-B*40:01 (aHR 0.29, 95% CI: 0.10-0.82) were protective for treatment failure related modification.

Conclusion: HLA-B*35:05 and female gender were strong predictors of regimen modification due to rash and lipodystrophy, respectively. Female gender, elder age, and having HLA-B*40:01 had protective effects on treatment failure-related regimen modification. This study provides further information of regimen modification for future tailored ART in Asia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recruitment of patients. ART, antiretroviral therapy.
Figure 2
Figure 2
Kaplan-Meier curve of regimen modification stratified by reasons.
See this image and copyright information in PMC

References

    1. Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. doi: 10.1097/01.qai.0000233310.90484.16. - DOI - PubMed
    1. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, Fox K, Thanprasertsuk S, Mock PA, Ningsanond P, Lertpiriyasuwat C, Pinyopornpanich S. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009;50(5):506–512. doi: 10.1097/QAI.0b013e3181967602. - DOI - PubMed
    1. Pathipvanich P, Tsuchiya N, Rojanawiwat A, Schmidt WP, Auwanit W, Sawanpanyalert P, Ariyoshi K. Changing burden of HIV/AIDS to clinical settings in Northern Thailand over 15 years. Jpn J Infect Dis. 2013;66(5):375–378. doi: 10.7883/yoken.66.375. - DOI - PubMed
    1. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff M, Pape JW, Leger P, Padgett D, Madero JS, Gotuzzo E, Sued O, McGowan CC, Masys DR, Cahn PE. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One. 2010;5(6):e10490. doi: 10.1371/journal.pone.0010490. - DOI - PMC - PubMed
    1. Zhou J, Paton NI, Ditangco R, Chen YM, Kamarulzaman A, Kumarasamy N, Lee CK, Li PC, Merati TP, Phanuphak P, Pujari S, Vibhagool A, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med. 2007;8(1):8–16. doi: 10.1111/j.1468-1293.2007.00417.x. - DOI - PMC - PubMed

Publication types

MeSH terms